**4. Conclusions**

The expansion of ART access comes with a growing concern for the rise in HIVDR. HIVDR monitoring is essential for effective HIV/AIDS managemen<sup>t</sup> at individual and population levels. Conventional Sanger sequencing-based HIVDR genotyping may not be readily assessable, especially in RLS, for logistical and operational reasons. POCT offers a quick and affordable solution administered at or near patient care. The assays explored here show the progression of each test, where they stand, and adjustments that need to be made. Although the work that has been done is impressive, no such assay entirely embodies the ASSURED criteria. A fully validated POCT that satisfies the set standards and meets all the needs for HIVDR diagnostics, especially in RLS, has ye<sup>t</sup> to be developed. More research still needs to be done as POCTs are indispensable in controlling the spread of drug-resistant HIV.

**Author Contributions:** Conceptualization, H.J.; Methodology, R.J.C., R.C. and H.J.; Writing—Original Draft Preparation, R.J.C.; Writing—Review & Editing, R.J.C., R.C. and H.J.; Supervision, H.J.; Project Administration, H.J. All co-authors made substantial contributions to this work. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work is funded, APC included, by the National Microbiology Laboratory Branch of the Public Health Agency of Canada, to which all co-authors are affiliated.

**Conflicts of Interest:** The authors declare no conflict of interest. The funder had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
